Publications by authors named "J Durant"
Article Synopsis
- - Varoglutamstat is a new small molecule being tested for early Alzheimer's disease, targeting glutaminyl cyclase to potentially reduce toxic forms of amyloid-β and neuroinflammatory cytokines.
- - The VIVA-MIND trial is structured in two phases, with phase 2A focusing on determining the safe dose and phase 2B evaluating the drug's effectiveness and long-term safety through a 72-week period.
- - The trial's design allows for continuous safety assessments and adaptive decision-making based on cognitive function and electroencephalogram changes, aiming to confirm varoglutamstat's unique ability to tackle several aspects of Alzheimer's pathology.
Population dynamics depend on trophic interactions that are affected by climate change. The rise in sea temperature is associated with the disappearance of sea ice in the Arctic. In the Arctic part of the Barents Sea, Atlantic cod, capelin and polar cod are three fish populations that interact and are confronted with climate-induced sea ice reductions.
View Article and Find Full Text PDFArticle Synopsis
- Conducted whole-genome sequencing on 263 cholera O1 isolates from four provinces in the Democratic Republic of Congo between 2018 and 2024, identifying them as part of the AFR10 lineage.
- The study revealed that while core genomic changes were minimal, significant rearrangements in the CTX prophage were noted in recent isolates from 2022-2024.
- AFR10e showed widespread distribution across provinces, while AFR10d appeared to be extinct after 2020, highlighting important shifts in cholera strain characteristics.
Article Synopsis
- Benfotiamine is being tested as a new oral treatment option for early Alzheimer's disease (AD), potentially enhancing the effects of existing therapies targeting amyloid.
- A 72-week randomized, double-blind, placebo-controlled trial will investigate its safety, tolerability, and efficacy in 406 participants, starting with a phase 2A to find the optimal dose before moving to phase 2B.
- The trial's innovative design allows for a smooth transition between phases, aiming to confirm benefits through specific cognitive and safety assessments.
Per- and polyfluoroalkyl substances (PFAS) are widely used in industry and have been linked to various adverse health effects. Communities adjacent to sites where PFAS are manufactured, stored, or used may be at elevated risk. In these impacted communities, significant exposure often occurs through contaminated drinking water, yet less is known about the role of other pathways such as residential exposure through house dust.
View Article and Find Full Text PDF